- Tytuł :
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- Autorzy :
- Źródło :
- In The Lancet 19 December 2020-1 January 2021 396(10267):1994-2005
-
Czasopismo naukowe